Mereo BioPharma Group (LON:MPH) Reaches New 12-Month Low at $40.19

Mereo BioPharma Group PLC (LON:MPH) reached a new 52-week low on Friday . The stock traded as low as GBX 40.19 ($0.53) and last traded at GBX 41.50 ($0.54), with a volume of 8727 shares trading hands. The stock had previously closed at GBX 45.50 ($0.59).

The company has a quick ratio of 2.05, a current ratio of 2.13 and a debt-to-equity ratio of 65.56. The stock has a market cap of $40.65 million and a P/E ratio of -0.92. The company’s 50-day moving average is GBX 61.57.

In other news, insider Anders Ekblom purchased 46,700 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The shares were bought at an average cost of GBX 109 ($1.42) per share, for a total transaction of £50,903 ($66,513.79). Also, insider Peter J. Fellner bought 30,000 shares of the company’s stock in a transaction on Monday, April 29th. The stock was bought at an average cost of GBX 128 ($1.67) per share, for a total transaction of £38,400 ($50,176.40).

Mereo BioPharma Group Company Profile (LON:MPH)

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.

See Also: Why is a lock-up period needed for an IPO?

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.